Weekly Roundup 6/05/09

J0145922 I am really sick of rain.  Really.  This morning there was a duck floating in my back yard.   A duck. 

Here is what happened this week that was interesting to me and I hope will be to you too.

  • FDA Sets Transparency Meeting –

The agency is on a transparency tear – taking down the curtains, raising the window shades and letting in the light.  After establishing a Transparency Task Force (though ironically, we don't know the names of the people on the Task Force) and a Transparency Web page, and a Transparency Blog (though we don't know who is writing it),  the agency has set a date for a Transparency Meeting, which will be held June 24 in Washington, D.C.

  • First Drug Approved for Cancer in Dogs – The FDA approvedPalladia, a tyrosine kinase inhibitor that kills tumor cells and cuts off the blood supply to a tumor.  The drug is brought to us dog lovers by Pfizer Animal Health.  For those of us who have been through this with our best friends, it may come as a surprise to know that current cancer treatments used on dogs are used off-label and have been approved for humans.  Palladia is the first that is canine-approved.  Thanks Pfizer!

  • Complete Response Letter Issued to ViroPharma- In response to the sBLA for its acute attacks of hereditary angioedema, ViroPharma received a Complete Response Letter asking for an additional clinical trial.  Though no safety concerns were mentioned, the motive on the part of the FDA was due to a stated "lack of robustness" in the Phase III clinical trial. 

Typepad is being highly temperamental today and hard to work with, so that is it for me this week.  Have a good and sunny weekend wherever you are. 

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
This entry was posted in Weekly Roundup. Bookmark the permalink.